Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tissue Engineering Applications in Breast Cancer Publisher Pubmed



Mahmoodi M1, 2 ; Ferdowsi S3 ; Ebrahimibarough S1 ; Kamian S4 ; Ai J1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technology in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Radiology, Faculty of Paramedical Sciences, Kurdistan University of Medical Sciences, Sanandaj, Iran
  3. 3. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
  4. 4. Department of Radiotherapy Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Journal of Medical Engineering and Technology Published:2020


Abstract

In Iran, breast cancer (BC) is the most prevalent cancer among women. The standard treatment for this cancer is partial or total removal of breast tissue, followed by chemotherapy and radiation. Tissue engineering (TE) has made new treatments for tissue loss in these patients by creating functional substitutes in the laboratory. In addition, cancer biology combined with TE provides a new strategy for evaluation of anti-BC therapy. Several innovations in TE have led to the design of scaffold or matrix based culture systems that more closely mimic the native extracellular matrix (ECM). Currently, engineered three-dimensional (3D) cultures are being developed for modelling of the tumour microenvironment. These 3D cultures fulfil the need for in vitro approaches that allow an accurate study of the molecular mechanisms and a better analysis of the drugs effect. In the present study, we review recent developments in utilising of TE in BC. Moreover, this review describes achievements of Iranian researchers in the field of breast TE. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.